Zobrazeno 1 - 10
of 254
pro vyhledávání: '"Yen-Shen Lu"'
Autor:
Huang-Chun Lien, Hui-Chieh Yu, Wen-Hsuan Yu, Su-Fang Lin, Tom Wei-Wu Chen, I-Chun Chen, Li-Ping Hsiao, Ling-Chun Yeh, Yu-Chia Li, Chiao Lo, Yen-Shen Lu
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-19 (2024)
Abstract Background Although tumor cells undergoing epithelial–mesenchymal transition (EMT) typically exhibit spindle morphology in experimental models, such histomorphological evidence of EMT has predominantly been observed in rare primary spindle
Externí odkaz:
https://doaj.org/article/9f78f937e516410bb7a31f55e1254237
Autor:
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib combined with t
Externí odkaz:
https://doaj.org/article/3cba658e7441401e9b9e50ad16a29171
Autor:
Huang-Chun Lien, Chiao Lo, Yi-Hsuang Lee, Po-Hang Lin, Ming-Yang Wang, Wen-Hung Kuo, Li-Wei Tsai, Yen-Shen Lu, Hsiang-Wei Hu, Yu-Chia Li, Chiun-Sheng Huang
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-15 (2024)
Abstract Background Immunohistochemistry (IHC) and in situ hybridization (ISH) remain standard biomarkers for therapeutic decisions in human epidermal growth factor 2 (HER2)-positive breast cancers (BCs); however, they are insufficient to explain the
Externí odkaz:
https://doaj.org/article/2448144cc977440f989584578a8341cf
Autor:
Ming‐Han Yang, Chiun‐Sheng Huang, Dwan‐Ying Chang, Fu‐Chang Hu, Shu‐Min Huang, Po‐Hsiang Huang, I‐Chun Chen, Tom Wei‐Wu Chen, Ching‐Hung Lin, Yen‐Shen Lu
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Background Due to cardiotoxicity concerns, the concurrent use of epirubicin and trastuzumab has not been fully studied. This study aimed to examine the cardiotoxicity and pathological complete response (pCR) rate associated with the concurre
Externí odkaz:
https://doaj.org/article/a4a2279cf2eb4e7d98df81b37c87cb9e
Autor:
Yi-Hsuan Lee, Chung-Yen Huang, Yu-Han Hsieh, Chia-Hung Yang, Yu-Ling Hung, Yung-An Chen, Yu-Chieh Lin, Ching-Hung Lin, Jih-Hsiang Lee, Ming-Yang Wang, Wen-Hung Kuo, Yen-Yin Lin, Yen-Shen Lu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are the two most common immune checkpoints targeted in triple-negative breast cancer (BC). Refining patient selection for immunotherapy is non-trivial and finding an
Externí odkaz:
https://doaj.org/article/f6690e509a6a4a4baf5dbc669f38d80f
Autor:
Shang‐Hsuan Peng, Ching‐Hung Lin, I‐Chun Chen, Ying‐Chun Shen, Dwan‐Ying Chang, Tom Wei‐Wu Chen, Shu‐Min Huang, Fu‐Chang Hu, Yen‐Shen Lu
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 20035-20051 (2023)
Abstract Background Immune checkpoint inhibitors have revolutionized the treatment of malignancies. However, disproportionate enrollment among races and ethnicities places the generalizability of global trial results in doubt. Methods In this systema
Externí odkaz:
https://doaj.org/article/f2126875af6f4e839f435b6c0218e311
Autor:
Wen-Cheng Chou, Wei-Ting Chen, Chun-Tse Kuo, Yao-Ming Chang, Yen-Shen Lu, Chia-Wei Li, Mien-Chie Hung, Chen-Yang Shen
Publikováno v:
Cell Reports, Vol 43, Iss 1, Pp 113641- (2024)
Summary: Immune checkpoint blockade (ICB) is a promising therapy for solid tumors, but its effectiveness depends on biomarkers that are not precise. Here, we utilized genome-wide association study to investigate the association between genetic varian
Externí odkaz:
https://doaj.org/article/a66408c1704e49fd8aded91f73aba11a
Autor:
Chun-Wen Cheng, Yu-Fan Liu, Wen-Ling Liao, Po-Ming Chen, Yueh-Tzu Hung, Huei-Jane Lee, Yu-Chun Cheng, Pei-Ei Wu, Yen-Shen Lu, Chen-Yang Shen
Publikováno v:
Cancers, Vol 16, Iss 3, p 657 (2024)
Hypoxia-inducible factor 1α (HIF-1α) plays a pivotal role in the survival, metastasis, and response to treatment of solid tumors. Autophagy serves as a mechanism for tumor cells to eliminate misfolded proteins and damaged organelles, thus promoting
Externí odkaz:
https://doaj.org/article/dfb42fb6606d4af994304f5d03682fd4
Autor:
Huang-Chun Lien, Chia-Lang Hsu, Yen-Shen Lu, Tom Wei-Wu Chen, I.-Chun Chen, Yu-Chia Li, Chiun-Sheng Huang, Ann-Lii Cheng, Ching-Hung Lin
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-17 (2023)
Abstract Background Metaplastic breast carcinoma (MpBC) typically consists of carcinoma of no special type (NST) with various metaplastic components. Although previous transcriptomic and proteomic studies have reported subtype-related heterogeneity,
Externí odkaz:
https://doaj.org/article/ae460c78f1664357b2b1e5a9d7202684
Autor:
Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G. C. A. Jackson, Noelyn Hung, Jianguo Zhi, David L. Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel (oPAC) may be more convenient, less resource-i
Externí odkaz:
https://doaj.org/article/c0df0803d9fb4cc49e7cf54109162455